In response to new economic and regulatory realities, CytoDyn, Inc. (Pink Sheet: CYDY) has made a sea change in its strategy for developing Cytolin®, the Company’s unique immune therapy for treating early HIV infection which is under a research study by Massachusetts General Hospital. With 18.8 million shares outstanding and 25 million available, it is grossly under priced even with the stock at $10.00 or even $20.00, which at those levels makes the market cap only $250-500 million.  Those figures are ridiculous as those valuations are typical of start-up bio-tech’s with little proven track records.  Therefore, it may be fair to say that pricing the stock at $40/share, which is a market cap of $1 billion, are they still under priced?  Who knows, but with those numbers and a worldwide rush to the doors to curb this growing disease, this company does show that a $5 Billion valuation is not unrealistic! You can go through the complete press release at: http://blog.insidecytolin.com/?p=203